These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 30213389

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
    Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM.
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27986884
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R.
    Curr Treat Options Oncol; 2018 Sep 10; 19(11):52. PubMed ID: 30203318
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS.
    Cancer; 2019 Sep 15; 125(18):3111-3120. PubMed ID: 31287161
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.
    Li L, Li Y, Que X, Gao X, Gao Q, Yu M, Ma K, Xi Y, Wang T.
    Sci Rep; 2018 Apr 19; 8(1):6267. PubMed ID: 29674626
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N, Uner A, Benekli M, Barista I.
    Cancer; 2012 Sep 01; 118(17):4173-83. PubMed ID: 22213394
    [Abstract] [Full Text] [Related]

  • 13. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA, Smith SM.
    Clin Lymphoma Myeloma Leuk; 2018 Feb 01; 18(2):91-97. PubMed ID: 29352717
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
    Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD.
    Blood; 2016 May 05; 127(18):2182-8. PubMed ID: 26834242
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.